A year has 8,760 hours. Support the campaign
Vitruvian Shield
Pharma sponsors

Built for pharma sponsors

Vitruvian Shield builds an AI-native clinical evidence platform for hybrid trials and post-market surveillance. Sponsors own the study and the EDC; CROs run the study; Vitruvian Shield supplies the evidence layer, working under both.

The challenges you face

Fragmented technology stacks

Managing separate vendors for CTMS, EDC, eConsent, ePRO, and RPM creates data silos, integration overhead, and compliance gaps between systems.

Slow enrolment and high dropout

Traditional site-based models limit the recruitment pool and burden patients with frequent clinic visits, which drives dropout in many indications.

Rising monitoring costs

On-site monitoring visits take a large share of trial budgets. Manual source data verification is slow and expensive, and still misses data-quality issues.

Regulatory complexity

Navigating FDA, EMA, and local authority requirements across multi-region trials requires constant vigilance and manual compliance tracking.

Limited real-world data capture

Episodic clinic-based assessments miss the continuous patient experience between visits, leaving gaps in safety signals and efficacy evidence.

How Vitruvian Shield helps

One evidence layer next to your EDC

The platform works alongside the EDC you already use. Device data, patient-reported outcomes and consent records arrive in one traceable dataset with an audit trail, so remote data does not need manual reconciliation.

Decentralised trial capabilities

Remote consent, home-based monitoring, and mobile ePRO let patients participate from anywhere. Reduce site dependency and expand your enrolment reach.

Risk-based monitoring built in

Centralised monitoring with data-quality checks, protocol-deviation tracking and targeted site alerts reduces the need for on-site visits. AI-assisted quality scoring and deviation prediction are in development.

Designed for regulated research

Designed to support ALCOA++ data-integrity principles, GDPR requirements, ICH E6(R3) and FDA 21 CFR Part 11. Automated audit trails and dashboards keep every study ready for inspection.

Continuous data capture

Device and patient-reported data stream between visits through a native research wearable, devices activated per study and camera-based contactless monitoring via rPPG (in validation). Capture safety signals, treatment response, and quality of life metrics between visits.